Advances of G protein coupled receptor 119 agonists and their structure-activity relationship

G Protein Coupled Receptor 119 (GPR119),expressed primarily in the pancreas,liver and gastrointestinal tract,is a new target for the treatment of type 2 diabetes mellitus (T2DM).GPR119 agonists can rise the level of intracellular cAMP,leading to increased glucose-dependent insulin,GLP-1 (glucagon-like peptide 1) and GIP (gastric inhibitory peptide) secretion.Therefore,they play an important role in the treatment of T2DM.This review summarizes the research progress on the structure-activity relationships of GPR119 agonists from different pharmaceutical companies and introduced our efforts in this field.